Medtronic to Acquire EPIX Therapeutics, Expanding Its Cardiac Ablation Portfolio

Medical Device Investing

Medtronic (NYSE:MDT) today announced that it has entered into a definitive agreement to acquire EPIX Therapeutics, Inc. (EPIX), a privately-held medical device company that designs and manufactures a novel, catheter-based, temperature-controlled cardiac ablation system for the treatment of patients with cardiac arrhythmias (irregular heartbeats), including atrial fibrillation (AF). When completed, the EPIX acquisition will expand …

Medtronic (NYSE:MDT) today announced that it has entered into a definitive agreement to acquire EPIX Therapeutics, Inc. (EPIX), a privately-held medical device company that designs and manufactures a novel, catheter-based, temperature-controlled cardiac ablation system for the treatment of patients with cardiac arrhythmias (irregular heartbeats), including atrial fibrillation (AF). When completed, the EPIX acquisition will expand the Medtronic cardiac ablation portfolio to offer physicians a comprehensive suite of tools to treat patients with cardiac arrhythmias.

As quoted in the press release:

EPIX’s flagship technology, the DiamondTemp(TM) ablation system, is a unique closed-loop, temperature-controlled system that provides physicians with improved feedback and control during an ablation procedure. The DiamondTemp system uses radiofrequency (RF) energy (heat) to create scar tissue in the heart and complements the Medtronic cryoballoon technology that uses cryo energy (cold) to isolate the pulmonary veins (PVI).

The DiamondTemp system received CE Mark in Europe in 2017 and is limited to investigational use in the U.S. The DIAMOND-AF trial, which completed enrollment in Oct. 2018, will support approval of the DiamondTemp system in the U.S. for patients with symptomatic paroxysmal AF (AF that starts and stops intermittently). Additionally, the DIAMOND-AF II trial, which is currently enrolling patients, is evaluating the DiamondTemp system in patients with persistent AF (AF that continues for long periods of time).

“The DiamondTemp ablation system stands out from other RF ablation technologies because of the real-time temperature control via rapid power modulation. This results in shorter procedure times and higher confidence in lesion quality,” said Atul Verma, M.D., Southlake Regional Health Center in Newmarket, Canada, and global principal investigator for the DIAMOND-AF II study. “I’ve had the pleasure of working with EPIX to design the DIAMOND-AF II trial and I look forward to continuing that work with Medtronic.”

Click here to read the full press release.

The Conversation (0)
Ă—